Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin

C Roux, Camille Roux, C Pélissier, C Pelissier, V Listrat, S Kolta, C Simonetta, M Guignard, Michel Guignard, Maxime Dougados, M Dougados, B Amor
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1995 · vol. 5(3) , pp. 185–190 · doi:10.1007/bf02106098 · PMID:7655179 · W2030452343
article OA: closed CC0 ⤵ 13 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

This study evaluated nasal salmon calcitonin's effectiveness in preventing bone loss in endometriosis patients treated with GnRH agonists, finding the doses insufficient to prevent bone loss.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 ⓘ

This prospective, double-masked randomized study evaluated whether nasal salmon calcitonin (sCT), at 100 IU or 200 IU daily, could prevent bone loss during GnRH agonist therapy in 40 patients with endometriosis treated for 6 months with triptorelin plus daily calcium. Bone mineral density was assessed by dual-energy X-ray absorptiometry along with biochemical markers of bone metabolism. After 6 months, estradiol and bone turnover markers were at postmenopausal levels and there were no differences between placebo and either sCT dose, with no difference in bone loss at any measured site. This paper is centrally about endometriosis — it tests nasal salmon calcitonin as a preventive adjunct to GnRH agonist–associated bone loss in women with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715

MeSH descriptors

Bone Diseases, Metabolic Bone Diseases, Metabolic Calcitonin Gonadotropin-Releasing Hormone Triptorelin Pamoate Absorptiometry, Photon Administration, Intranasal Adult Animals Bone Density Bone Density Bone Diseases, Metabolic Calcitonin Calcitonin Calcitonin Double-Blind Method Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (13)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T16:23:13.998983+00:00
pubmed
last seen: 2026-05-13T22:11:13.665691+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK